Radius Health Inc (RDUS)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Robert E. Ward
Employees:
398
ATTN: CHIEF FINANCIAL OFFICER, 950 WINTER STREET, WALTHAM, MA 02451
617-551-4000

Radius Health, Inc. a biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of osteoporosis and other women health conditions. Its BA058 Injection product is a daily subcutaneous injection of novel synthetic peptide analog of human parathyroid hormone-related protein. The company also develops BA058 Microneedle Patch; RAD1901, a selective estrogen receptor modulator for the treatment of vasomotor symptoms in women entering menopause; and RAD140, a selective androgen receptor modulator. Its initial business was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts on October 3, 2003. Radius Health was founded on February 4, 2008 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 296.142 Million Shares Outstanding47.383 Million Avg 30-day Volume 875.787 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-15.749 Million
Price to Revenue3.477 Debt to Equity-1.9291 EBITDA-62.615 Million
Price to Book Value0.0 Operating Margin-34.5375 Enterprise Value953.031 Million
Current Ratio2.467 EPS Growth0.187 Quick Ratio1.845
1 Yr BETA 1.3044 52-week High/Low 23.0 / 4.97 Profit Margin-45.7617
Operating Cash Flow Growth10.2725 Altman Z-Score-7.7606 Free Cash Flow to Firm -65.459 Million
Earnings Report2022-08-04
View SEC Filings from RDUS instead.

View recent insider trading info

Funds Holding RDUS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RDUS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

477.8 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BIOTECH TARGET N V

BB BIOTECH AG

  • 10% Owner
8,733,538 2022-05-18 4

JARRETT JENNIFER

  • Director
0 2022-05-18 2

LISA SUSAN VISSERS

  • Director
0 2022-05-18 2

CONLEY MARK WILLIAM VP, CHIEF FINANCIAL OFFICER

  • Officer
50,000 2022-03-15 2

MARTIN G. KELLY CEO AND PRESIDENT

  • Officer
  • Director
75,000 2022-02-21 2

MESSERSMITH ELIZABETH SENIOR VICE PRESIDENT

  • Officer
70,000 2022-02-16 1

GARNIER JEAN PIERRE

  • Director
36,800 2022-01-14 1

DERE WILLARD H

  • Director
33,195 2022-01-14 1

FRIEDMAN CATHY

  • Director
36,800 2022-01-14 1

VON ESCHENBACH ANDREW C.

  • Director
15,500 2022-01-14 1

HUGHES OWEN

  • Director
31,650 2022-01-14 1

MURPHY SEAN

  • Director
21,000 2022-01-14 1

SANDERS MACHELLE

  • Director
15,500 2022-01-14 1

SHAH CHHAYA CHIEF BUSINESS OFFICER

  • Officer
94,645 2022-01-14 1

HELWIG STEVEN PRINCIPAL FINANCIAL OFFICER

  • Officer
31,251 2022-01-14 3

HOLTSCHLAG DANIELLE VICE PRESIDENT, SALES

  • Officer
25,000 2022-01-14 3

RUBRIC CAPITAL MANAGEMENT LP

ROSEN DAVID EFRAIM

  • 10% Owner
6,959,305 2021-12-16 4

RUBRIC CAPITAL MANAGEMENT LP

  • 10% Owner
4,756,876 2021-12-08 4

CHOPAS JAMES GEORGE PRINCIPAL FINANCE ACCOUNTING

  • Officer
6,701 2021-03-05 0

GRAUSSO SAL CHIEF COMMERCIAL OFFICER

  • Officer
11,709 2021-02-25 0

DOLAN DAN VP OF FINANCE

  • Officer
0 2020-11-09 0

ROSENBERG ANTHONY

  • Director
12,401 2020-02-26 0

MORRIS CHARLES Q CHIEF MEDICAL OFFICER

  • Officer
33,744 2020-02-26 0

CARMONA JOSE CHIEF FINANCIAL OFFICER

  • Officer
46,708 2020-02-26 0

KELLY JOSEPH FRANCIS SR. VP OF SALES AND MARKETING

  • Officer
24,111 2020-02-26 0

GRAVES KURT

  • Director
11,000 2020-02-20 0

HOPFIELD JESSICA

  • Director
18,300 2020-02-20 0

HOEILAND JESPER PRESIDENT AND CEO

  • Officer
  • Director
0 2020-02-20 0

BIOTECH GROWTH N V

BB BIOTECH AG

  • 10% Owner
6,881,685 2019-11-06 0

ROYCHOWDHURY DEBASISH

  • Director
5,500 2019-04-11 0

HATZIS-SCHOCH BRENT SR. VP, GENERAL COUNSEL

  • Officer
17,944 2019-02-22 0

HATTERSLEY GARY CHIEF SCIENTIFIC OFFICER

  • Officer
No longer subject to file 2018-12-31 0

FITZPATRICK LORRAINE A. CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2018-12-31 0

WILLIAMS GREGORY C. CHIEF DEVELOPMENT OFFICER

  • Officer
0 2018-02-13 0

SNOW DAVID P. CHIEF COMMERCIAL OFFICER

  • Officer
No longer subject to file 2017-12-31 0

HARVEY BRIAN NICHOLAS SR. VP AND CFO

  • Officer
76,189 2017-04-25 0

GADICKE ANSBERT

  • Director
0 2017-02-17 0

AUERBACH ALAN H

  • Director
0 2017-02-17 0

WARD ROBERT PRESIDENT & CEO

  • Officer
  • Director
0 2017-02-17 0

PURANDARE DINESH SVP, HEAD OF GLOBAL ONCOLOGY

  • Officer
0 2017-02-17 0

EVNIN LUKE

  • FORMER 10% STOCKHOLDER
No longer subject to file 2016-09-27 0

MPM BIOVENTURES III LLC

HENNER DENNIS

MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC

MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG

MPM BIOVENTURES III PARALLEL FUND, L.P.

MPM BIOVENTURES III GP L.P.

MPM BIOVENTURES III L.P.

MPM BIOVENTURES III-QP L.P.

STEINMETZ MICHAEL

  • FORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDER
No longer subject to file 2016-09-27 0

MPM BIOVENTURES IV LLC

SCOPA JAMES PAUL

MPM BIOVENTURES IV GP LLC

MPM BIO IV NVS STRATEGIC FUND LP

KAILIAN VAUGHN M

FOLEY TODD

  • FORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDER
No longer subject to file 2016-09-27 0

GALAKATOS NICHOLAS

SIMON NICHOLAS J III

WHEELER KURT

  • FORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDER
No longer subject to file 2016-09-27 0

WARD ROB PRESIDENT & CEO

  • Officer
  • Director
0 2015-10-21 0

MUENCHBACH MARTIN

  • Director
0 2015-05-07 0

F2 BIOSCIENCE III, L.P.

F2 BIOSCIENCE GP LTD.

F2 CAPITAL LTD

PRIESTLEY KATHERINE

GLOBEWAYS HOLDINGS LTD

  • 10% Owner
No longer subject to file 2015-01-16 0

F2 BIOSCIENCE IV L.P.

F2 BIOSCIENCE IV GP LTD.

F2 CAPITAL LTD

PRIESTLEY KATHERINE

F2 BIO VENTURES V L.P.

F2 BIO VENTURES GP LTD.

GLOBEWAYS HOLDINGS LTD

  • 10% Owner
No longer subject to file 2015-01-16 0

JOVAN-EMBIRICOS MORANA

  • Director
  • 10% Owner
3,834,831 2015-01-08 0

F2 BIOSCIENCE III, L.P.

F2 BIOSCIENCE GP LTD.

F2 CAPITAL LTD

PRIESTLEY KATHERINE

  • 10% Owner
1,167,997 2015-01-08 0

HARRIS ALAN G CHIEF MEDICAL OFFICER

  • Officer
0 2014-12-17 0

STONER ELIZABETH

  • Director
0 2014-12-17 0

F2 BIOSCIENCE IV L.P.

F2 BIOSCIENCE IV GP LTD.

F2 CAPITAL LTD

PRIESTLEY KATHERINE

F2 BIO VENTURES V L.P.

F2 BIO VENTURES GP LTD.

GLOBEWAYS HOLDINGS LTD

F2 BIOSCIENCE VI L.P.

  • 10% Owner
3,254,334 2014-06-11 0

F2 BIOSCIENCE VI L.P.

F2 CAPITAL LTD

PRIESTLEY KATHERINE

GLOBEWAYS HOLDINGS LTD

F2 BIOSCIENCE IV GP LTD.

  • 10% Owner
587,500 2014-06-11 0

DURAND MARK CHIEF COMMERCIAL OFFICER

  • Officer
0 2014-06-05 0

MPM BIOVENTURES IV LLC

SCOPA JAMES PAUL

VANDER VORT JOHN

MPM BIOVENTURES IV GP LLC

MPM BIO IV NVS STRATEGIC FUND LP

FOLEY TODD

KAILIAN VAUGHN M

  • 10% Owner
179,095 2013-04-23 0

WELLCOME TRUST LTD (THE) AS TRUSTEE OF THE WELLCOME TRUST

  • 10% Owner
0 2011-12-14 0

MPM BIOVENTURES IV LLC

MPM BIOVENTURES IV GP LLC

MPM BIO IV NVS STRATEGIC FUND LP

FOLEY TODD

KAILIAN VAUGHN M

SCOPA JAMES PAUL

ST PETER STEVEN

VANDER VORT JOHN

  • 10% Owner
0 2011-12-14 0

FLEMING JONATHAN

  • Director
0 2011-12-14 0

HEALTHCARE VENTURES VII LP

HEALTHCARE PARTNERS VII, L.P.

CAVANAUGH JAMES H

LAWLOR AUGUSTINE

LITTLECHILD JOHN W

MIRABELLI CHRISTOPHER

WERNER HAROLD R

  • 10% Owner
0 2011-11-18 0

LYTTLE CECIL RICHARD PRESIDENT AND CEO

  • Officer
  • Director
0 2011-11-07 0

O'DEA LOUIS SR. VP, CHIEF MEDICAL OFFICER

  • Officer
0 2011-11-07 0

MPM BIOVENTURES IV LLC

MPM BIOVENTURES IV GP LLC

MPM BIO IV NVS STRATEGIC FUND LP

DOMBKOWSKI ASHLEY L

GREENE WILLIAM

KAILIAN VAUGHN M

SCOPA JAMES PAUL

ST PETER STEVEN

VANDER VORT JOHN

  • 10% Owner
0 2011-05-17 0

IPSEN PHARMA SAS

IPSEN, S.A.

  • 10% Owner
  • POSSIBLE 10% BENEFICIAL OWNER
0 2011-05-17 0

ST PETER STEVEN PRESIDENT

  • Officer
  • Director
0 2008-06-15 0

VANDER VORT JOHN SECRETARY

  • Officer
  • Director
0 2008-06-15 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

BIOTECH TARGET N V - > 10% Owner

BB BIOTECH AG - > 10% Owner

2022-05-20 11:35:04 -0400 2022-05-18 P 477,824 $5.57 a 8,733,538 direct

LISA SUSAN VISSERS - Director

2022-05-20 18:01:19 -0400 2022-05-18 A 30,000 a 30,000 direct

JARRETT JENNIFER - Director

2022-05-20 17:56:52 -0400 2022-05-18 A 30,000 a 30,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
RADIUS HEALTH INC RDUS 2022-05-20 22:15:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 21:45:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 21:15:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 20:45:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 20:15:05 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 19:45:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 19:15:04 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 18:45:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 18:15:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 17:45:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 17:15:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 16:45:04 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 16:15:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 15:45:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 15:15:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 14:45:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 14:15:04 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 13:45:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 13:15:03 UTC 0.4111 0.4089 100000
RADIUS HEALTH INC RDUS 2022-05-20 12:45:03 UTC 0.4111 0.4089 100000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund RDUS -1200.0 shares, $-14892.0 2021-09-30 N-PORT
Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio RDUS -19600.0 shares, $-243236.0 2021-09-30 N-PORT

Elevate your investments